What If a Drug-Checking Sample Lacks the Drug the Submitter Expected?

Short answer: If a checked sample does not contain the drug the submitter expected, an unexpected opioid finding may reflect a mistaken or misrepresented sample rather than an opioid added to a confirmed expected drug. Wallace and colleagues treated these as different scenarios in their British Columbia analysis.

What was compared?

The researchers reviewed 8,889 samples not expected to contain fentanyl. They found unexpected opioids in 189, or about 2%. They then asked two questions for each result: was the expected compound actually detected, and was the opioid present at trace or greater concentration? The answers changed the interpretation. Unexpected opioids were more likely when the expected drug was absent.

Why is the expected-drug result essential?

Suppose a submitted material was believed to be cocaine. If cocaine is not confirmed, a positive opioid result cannot be described as “fentanyl in confirmed cocaine” based on that sample. If cocaine and an opioid are both confirmed, the co-presence question is different. A trace signal still deserves distinct treatment from a clearly above-trace finding. These labels reflect analytical evidence, not an automatic conclusion about intentional adulteration.

What can be said about a person?

A drug-checking result describes the tested item. It does not establish that a particular person consumed that same material, the dose they received or the cause of an event. Preserve the submitted-sample history, chain of custody, full compound list, method and quantitative classification. Biological specimens and the clinical timeline may be needed for an individual case.

This study’s submitted samples are not a random survey of all street drugs. The site’s earlier trace-detection article addresses the level of unexpected opioid; this one addresses the separate question whether the expected drug was there at all.

Scientific source

Wallace et al. Is fentanyl in everything? Examining the unexpected occurrence of illicit opioids in British Columbia drug checking samples. Harm Reduction Journal. 2025. doi:10.1186/s12954-025-01189-w.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Does Naloxone in a Xylazine-Positive Urine Sample Prove an Overdose Rescue?

Naloxone appeared in 156 of 413 xylazine-positive urine samples in Holt and colleagues’ outpatient testing cohort. That finding alone does not prove a recent overdose or emergency reversal. What the paper counted The researchers reviewed provider-ordered urine toxicology tests from April 2021 through March 2022. In their xylazine-positive group, 156…

Spread the love

Read Article: Does Naloxone in a Xylazine-Positive Urine Sample Prove an Overdose Rescue?

Did Three Overdose-Associated Toronto Samples Prove Xylazine Caused Those Events?

Three of 46 xylazine-positive submissions to Toronto’s Drug Checking Service were associated with a reported overdose. The paper does not establish that xylazine caused any of those three events. What the report actually counted Bowles and colleagues studied drug-checking submissions, not a controlled comparison of overdose outcomes. Within a September…

Spread the love

Read Article: Did Three Overdose-Associated Toronto Samples Prove Xylazine Caused Those Events?

What If a Drug-Checking Sample Lacks the Drug the Submitter Expected?

Short answer: If a checked sample does not contain the drug the submitter expected, an unexpected opioid finding may reflect a mistaken or misrepresented sample rather than an opioid added to a confirmed expected drug. Wallace and colleagues treated these as different scenarios in their British Columbia analysis. What was…

Spread the love

Read Article: What If a Drug-Checking Sample Lacks the Drug the Submitter Expected?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us